DC1 Vaccine

Phase 1Vaccine

HH. Lee Moffitt Cancer Center and Research Institute

DC1 Vaccine is one of 12 biologic programs targeting Breast Cancer Metastatic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast Cancer MetastaticActive, not recruiting

Breast Cancer MetastaticPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Breast Cancer Metastatic

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

1 2

Gemzar

Johnson & Johnson

Phase 2

1 3

Halaven

Eisai

Phase 2

1 4

Herceptin

OOrganon and Co

Phase 2

3 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 6

Navelbine

PPierre Fabre Medicament

Phase 2

1 7

Trastuzumab Deruxtecan

AstraZeneca

Phase 2

1 8

Evorpacept

AALX Oncology Inc.

Phase 2

1 9

Orserdu

SStemline Therapeutics, Inc.

Phase 1

1 10

Lynparza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Breast Cancer Metastatic

NCT06691035

Phase 2Active, not recruiting

Breast Cancer

NCT03384914

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03384914·119 enrolled

Prostate Cancer1 trial

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00970203·13 enrolled

Metastatic Colorectal Cancer1 trial

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

Withdrawn·PPawel Kalinski·Phase 2·NCT02615574

Breast Cancer Metastatic1 trial

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06691035·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DC1 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DC1 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DC1 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

DC1 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer1 trial

Prostate Cancer1 trial

Metastatic Colorectal Cancer1 trial

Breast Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News